Twitxy Saved

CytoReason

Verified account This account is verified. Learn more

@Cytoreason

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models.
Israel cytoreason.com Joined February 2018
1.1K Following 662 Followers 584 Posts

Latest posts 5

CytoReason Verified account @Cytoreason
What separates good pharma companies from great ones isn't the amount of data they have.

It's the quality of the biological decisions they make using their data. That starts with a real understanding of disease biology.

Because you can only be confident in a decision when you understand the biology behind it.

Target selection. Indication prioritization. Combination Design. Patient population prioritization. Get those right, and everything downstream improves.
CytoReason Verified account @Cytoreason
Strong AI and biology capabilities tend to pull companies in one direction.

They build pipelines and develop drugs. They become the competition.

We chose a different path.

CytoReason was built to help pharma make better decisions, not to replace pharma.

We will never develop drugs. That's not a loophole. It's a deliberate design choice.
CytoReason Verified account @Cytoreason
Most Phase II failures aren’t random.

They’re driven by molecular signals that are visible early in development.

Pharma generates enormous amounts of data, yet decisions still rely on fragmented views of biology.

The gap isn’t more data.

It’s turning molecular signals into a system you can actually decide with.
7 replies 13 reposts 128 likes 3.3M views View on X
CytoReason Verified account @Cytoreason
Biopharma doesn’t have a data problem. It has a decision problem.

Billions go into generating data, but critical R&D decisions still rely on fragmented views of biology.

What’s missing is a way to turn biology into something researchers can trust.

The winners won’t be the ones who collect more data. They’ll be the ones who know what to do with it.
39 replies 126 reposts 2K likes 20M views View on X
CytoReason Verified account @Cytoreason
Everyone is building an AI platform.

That’s not the hard part.

The hard part is keeping it grounded in human biology as new data comes in.

Models can improve on paper while drifting from biological reality.

The platforms that stay anchored in real biology are the ones that hold up, and drive better decisions over time.